press release

LAWSUITS FILED AGAINST GATO, ABBV and AUPH - Jakubowitz Law Pursues Shareholders Claims

2022-04-21

TSX - Toronto Stock Exchange · Copper · Molybdenum · Silver · Gold · Zinc · Lead · Germanium · Indium · Sulfur · Nickel · Platinum · Palladium · Legal Matters

NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Gatos Silver, Inc. (NYSE:GATO)

CONTACT JAKUBOWITZ ABOUT GATO: https://claimyourloss.com/securities/gatos-silver-inc-loss-submission-form/?id=26238&from=1

This lawsuit is on behalf of persons and entities that purchased or otherwise acquired Gatos: (a) common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about October 28, 2020; and/or (b) securities between October 28, 2020 and January 25, 2022, inclusive.

Lead Plaintiff Deadline : April 25, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the technical report for Gatos's primary mine, the Cerro Los Gatos deposit, contained certain errors; (2) among other things, the mineral reserves had been overestimated by as much as 50%; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

AbbVie Inc. (NYSE:ABBV)

CONTACT JAKUBOWITZ ABOUT ABBV: https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=26238&from=1

Class Period : April 30, 2021 - August 31, 2021

Lead Plaintiff Deadline : June 6, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) safety concerns about Pfizer Inc.'s drug Xeljanz extended to Abbvie's drug Rinvoq and to other Janus kinase enzyme inhibitor drugs; (2) as a result, it was likely that the U.S. Food and Drug Administration would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

CONTACT JAKUBOWITZ ABOUT AUPH: https://claimyourloss.com/securities/aurinia-pharmaceuticals-inc-loss-submission-form/?id=26238&from=1

Class Period : May 7, 2021 - February 25, 2022

Lead Plaintiff Deadline : June 14, 2022

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Aurinia was experiencing declining revenues; (ii) Aurinia's 2022 sales outlook for the Company's only product which it offers for the treatment of adult patients with active lupus nephritis, LUPKYNIS, would fall well short of expectations; (iii) accordingly, the Company had significantly overstated LUPKYNIS's commercial prospects; (iv) as a result, the Company had overstated its financial position and/or prospects for 2022; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: JAKUBOWITZ LAW 1140 Avenue of the Americas 9th Floor New York, New York 10036 T: (212) 867-4490 F: (212) 537-5887

SOURCE : Jakubowitz Law

View source version on accesswire.com: https://www.accesswire.com/698339/LAWSUITS-FILED-AGAINST-GATO-ABBV-and-AUPH--Jakubowitz-Law-Pursues-Shareholders-Claims